Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4352-4355

  Keller, Peter M ^a   Hömke, Rico ^a   Ritter, Claudia ^a   Valsesia, Giorgia ^a   Bloemberg, Guido V ^a   Böttger, Erik C ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; DELAMANID; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATION; GROWTH REGULATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; VARIABLE NUMBER OF TANDEM REPEAT; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; REFERENCE VALUE; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZOLES; REFERENCE VALUES; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84935841157     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00614-15     Document Type: Article

References (24)

1. World Health Organization. 2015. Global tuberculosis report 2014. World Health Organization, Geneva, Switzerland. http://www.who.int/tb /publications/global-report/en/. Accessed 9 May 2015.
2. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. http://dx.doi.org/10.1126/science.1106753.
3. Cox E, Laessig K. 2014. FDA approval of bedaquiline-the benefit-risk balance for drug-resistant tuberculosis. N Engl J Med 371:689-691. http: //dx.doi.org/10.1056/NEJMp1314385.
4. Segala E, Sougakoff W, Nevejans-Chauffour A, Jarlier V, Petrella S. 2012. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob Agents Chemother 56:2326-2334. http://dx .doi.org/10.1128/AAC.06154-11.
5. Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A. 2014. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 9:e102135. http://dx.doi.org/10 .1371/journal.pone.0102135.
6. Somoskovi A, Bruderer V, Homke R, Bloemberg GV, Böttger EC. 2015. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 45:554-557. http://dx.doi.org/10.1183/09031936.00142914.
7. Tiberi S, De Lorenzo S, Centis R, Viggiani P, D'Ambrosio L, Migliori GB. 2014. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 43:289-292. http://dx.doi.org/10.1183/09031936.00122313.
8. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. 2006. OPC-67683, a nitrodihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3:e466. http://dx.doi.org/10.1371/journal.pmed.0030466.
9. European Medicines Agency, Committee for Medicinal Products for Human Use. 2013. Assessment report Deltyba. European Medicines Agency. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002552/WC500166234.pdf.
10. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966. http://dx.doi.org/10.1038/35016103.
11. Feuerriegel S, Köser CU, Bau D, Rusch-Gerdes S, Summers DK, Archer JA, Marti-Renom MA, Niemann S. 2011. Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. Antimicrob Agents Chemother 55:5718-5722. http://dx.doi.org /10.1128/AAC.05500-11.
12. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells CD, Paccaly AJ, Donald PR. 2011. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 15:949-954. http://dx.doi.org/10.5588/ijtld.10.0616.
13. Köser CU, Feuerriegel S, Summers DK, Archer JA, Niemann S. 2012. Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. Antimicrob Agents Chemother 56:6080-6087. http://dx.doi.org/10.1128/AAC.01641-12.
14. Springer B, Lucke K, Calligaris-Maibach R, Ritter C, Böttger EC. 2009. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol 47: 1773-1780. http://dx.doi.org/10.1128/JCM.02501-08.
15. Janssen Products. 2012. Highlights of prescribing information Sirturo (bedaquiline) tablets. Janssen Pharmaceutical Research and Development LLC, Titusville, NJ, USA. http://www.accessdata.fda.gov/drugsatfda-docs /label/2012/204384s000lbl.pdf.
16. Otsuka Novel Products GmbH. 2012. Annex I. Summary of product characteristics. Otsuka Novel Products GmbH, Munich, Germany. http: //ec.europa.eu/health/documents/community-register/2014/2014042812 6881/anx-126881-en.pdf.
17. Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T. 2012. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 90:693-698. http://dx .doi.org/10.2471/BLT.11.096644.
18. Turnidge J, Kahlmeter G, Kronvall G. 2006. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 12:418-425. http: //dx.doi.org/10.1111/j.1469-0691.2006.01377.x.
19. Turnidge J, Paterson DL. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 20:391-408. http://dx.doi.org/10 .1128/CMR.00047-06.
20. Valsesia G, Hombach M, Maurer FP, Courvalin P, Roos M, Böttger EC. 2015. A statistical approach for determination of disk diffusion-based cutoff values for systematic characterization of wild-type and nonwild-type bacterial populations in antimicrobial susceptibility testing. J Clin Microbiol 53:1812-1822. http://dx.doi.org/10.1128/JCM.03506-14.
21. Upton AM, Cho S, Yang TJ, Kim Y, Wang Y, Lu Y, Wang B, Xu J, Mdluli K, Ma Z, Franzblau SG. 2015. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:136-144. http://dx.doi.org/10.1128/AAC .03823-14.
22. Rouan MC, Lounis N, Gevers T, Dillen L, Gilissen R, Raoof A, Andries K. 2012. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother 56:1444-1451. http://dx.doi.org/10.1128/AAC.00720-11.
23. Böttger EC. 2011. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 17:1128-1134. http://dx.doi .org/10.1111/j.1469-0691.2011.03551.x.
24. Köser CU, Javid B, Liddell K, Ellington MJ, Feuerriegel S, Niemann S, Brown NM, Burman WJ, Abubakar I, Ismail NA, Moore D, Peacock SJ, Török ME. 2015. Drug-resistance mechanisms and tuberculosis drugs. Lancet 385:305-307. http://dx.doi.org/10.1016/S0140-6736(14)62450-8.